- Home
- DOUG vs AARD Comparison
DOUG vs AARD Comparison
Compare DOUG & AARD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | DOUG | AARD |
|---|---|---|
| Founded | 1911 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Building operators | Biotechnology: Pharmaceutical Preparations |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 178.2M | 165.8M |
| IPO Year | 2021 | 2025 |
Fundamental Metrics
Financial Performance| Metric | DOUG | AARD |
|---|---|---|
| Price | $1.81 | $5.30 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 9 |
| Target Price | N/A | ★ $15.29 |
| AVG Volume (30 Days) | ★ 409.6K | 106.7K |
| Earning Date | 05-05-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 118.68 | 43.11 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $955,578,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $1.53 | $3.35 |
| 52 Week High | $3.19 | $17.94 |
Technical Indicators
Market Signals| Indicator | DOUG | AARD |
|---|---|---|
| Relative Strength Index (RSI) | 45.95 | 44.11 |
| Support Level | $1.68 | $5.12 |
| Resistance Level | $1.84 | $6.43 |
| Average True Range (ATR) | 0.07 | 0.81 |
| MACD | -0.02 | -0.14 |
| Stochastic Oscillator | 21.43 | 22.17 |
Price Performance
Historical ComparisonAbout DOUG Douglas Elliman Inc.
Douglas Elliman Inc is engaged in the real estate services business and seeks to acquire or invest in additional real estate services businesses. The Company also offers, through its subsidiaries and ventures, development marketing services and ancillary services, including mortgage, title, and escrow services. It generates revenue from commissions and other brokerage income, property management, and other ancillary services.
About AARD Aardvark Therapeutics Inc.
Aardvark Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing novel, small-molecule therapeutics to activate innate homeostatic pathways for the treatment of metabolic diseases. It is focused on on developing selective compounds, targeting Bitter Taste Receptors (TAS2Rs) for hunger-associated conditions. Its product candidate, ARD-101, is an oral gut-restricted small-molecule agonist of certain TAS2Rs expressed in the gut lumen for which have initiated a Phase 3 clinical trial for hyperphagia associated with PWS.